

CCN3 Antibody

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H M R Mk	Endogenous	43	Rabbit	#P48745	4856

Product Usage Information**Application**

Western Blotting

Dilution

1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

Specificity/Sensitivity

CCN3 Antibody recognizes endogenous levels of total CCN3 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg118 of human CCN3 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

CCN3, also named NOV (Nephroblastoma overexpressed), belongs to the CCN (Cyr61, Ctgf, NOV) family of proteins. It is a cystine-rich secretory protein that associates with components of the extracellular matrix. Like other CCN family members, CCN3 is capable of mediating diverse biological functions through its four distinct domains, which enable binding to numerous protein partners (1-5).

CCN3 modulates bone turnover through various mechanisms and is implicated in the progression of primary bone cancers such as osteosarcoma and chondrosarcoma (6-8). Research has shown that CCN3 is also involved in the bone metastasis of melanoma, breast cancer, and prostate cancers (9-11). Recently, CCN3 was reported to play an important role in stem cell renewal (12). CCN3 is normally expressed in both embryonic and adult tissues (13,14). The activity of CCN3 is influenced by post translational modifications and proteolytic cleavage (15,16).

Background References

1. Perbal, B. (2001) *Mol Pathol* 54, 57-79.
2. Brigstock, D.R. et al. (2003) *Mol Pathol* 56, 127-8.
3. Leask, A. and Abraham, D.J. (2006) *J Cell Sci* 119, 4803-10.
4. Yeager, H. and Perbal, B. (2007) *J Cell Commun Signal* 1, 159-64.
5. McCallum, L. and Irvine, A.E. (2009) *Blood Rev* 23, 79-85.
6. Perbal, B. et al. (2008) *Clin Cancer Res* 14, 701-9.
7. Tzeng, H.E. et al. (2011) *J Cell Physiol* 226, 3181-9.
8. Yang, W. et al. (2011) *Hum Reprod* 26, 2850-60.
9. Vallacchi, V. et al. (2008) *Cancer Res* 68, 715-23.
10. Ouellet, V. et al. (2011) *Am J Pathol* 178, 2377-88.
11. Chen, P.C. et al. (2012) *Carcinogenesis* 33, 937-45.
12. Gupta, R. et al. (2007) *Science* 316, 590-3.
13. Burren, C.P. et al. (1999) *J Clin Endocrinol Metab* 84, 1096-103.
14. Kocalkowski, S. et al. (2001) *Anat Embryol (Berl)* 203, 417-27.
15. Perbal, B. et al. (1999) *Proc Natl Acad Sci U S A* 96, 869-74.
16. Su, B.Y. et al. (2001) *Mol Pathol* 54, 184-91.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human **M:** Mouse **R:** Rat **Mk:** Monkey

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.